U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07920393) titled 'Allogeneic Cell Therapy in Refractory T-Cell Lymphoma' on Oct. 10.
Brief Summary: The REACT study is for people with a rare type of cancer called T-cell lymphoma. T-cell lymphoma affects cells that are part of the body's immune system.
Most lymphomas develop from B cells. Lymphomas that develop from T cells are much rarer. There are several different types of T-cell lymphoma, and many of them grow quickly. Without treatment, people with aggressive T-cell lymphoma may die within weeks or months. Even when the first treatment is successful, only about 25 to 40 out of 100 patients are still alive without the lymphoma returning two year...